Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBIT (2016 - 2025)

Historic EBIT for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$26.3 million.

  • Capricor Therapeutics' EBIT fell 10203.14% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.7 million, marking a year-over-year decrease of 10667.89%. This contributed to the annual value of -$42.6 million for FY2024, which is 7678.0% down from last year.
  • Capricor Therapeutics' EBIT amounted to -$26.3 million in Q3 2025, which was down 10203.14% from -$27.7 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' EBIT peaked at -$1.3 million during Q4 2023, and registered a low of -$27.7 million during Q2 2025.
  • For the 5-year period, Capricor Therapeutics' EBIT averaged around -$9.8 million, with its median value being -$7.7 million (2023).
  • Per our database at Business Quant, Capricor Therapeutics' EBIT soared by 8411.56% in 2023 and then crashed by 50078.74% in 2024.
  • Over the past 5 years, Capricor Therapeutics' EBIT (Quarter) stood at -$6.4 million in 2021, then decreased by 26.44% to -$8.1 million in 2022, then surged by 84.12% to -$1.3 million in 2023, then plummeted by 500.79% to -$7.7 million in 2024, then tumbled by 241.45% to -$26.3 million in 2025.
  • Its EBIT stands at -$26.3 million for Q3 2025, versus -$27.7 million for Q2 2025 and -$7.7 million for Q4 2024.